Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NA DC Vaccine and Nivolumab as Adjuvant Treatment in Resected HCC and CRLM
NCT04912765Phase 2Recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neoantigen dendritic cell vaccine in hepatocellular carcinoma (HCC) and colorectal cancer (CRC), sponsored by National Cancer Centre Singapore. Primary endpoints: Relapse Free Survival at 24 months and Induced immune response against vaccinated NAs up to 2 years. Started Apr 2021; status: recruiting.
02
Drugs
neoantigen dendritic cell vaccine
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04912765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912765.